Published August 8, 2014
Nitesh D. Kuhadiya, MD, MPH, assistant professor of medicine, has received the Helmsley Charitable Trust Abstract Award from the Endocrine Society for his groundbreaking research that shows significant improvements in glucose control in patients with Type 1 diabetes.
Kuhadiya’s research — the first randomized, double-blinded, placebo-controlled trial of liraglutide in Type 1 diabetes — shows that the injectable drug benefits Type 1 diabetes patients when used in conjunction with insulin.
“This is important, as approximately 40 percent of patients with Type 1 diabetes in the United States now have metabolic syndrome, and liraglutide targets three out of the five key features: high blood pressure, diabetes and obesity,” Kuhadiya explains.
Results show several additional benefits of the combined treatment, including reductions in total insulin dose, average blood sugar measurement over 90 days, body weight, carbohydrate intake, C-reactive protein and systolic blood pressure — the upper reading in blood pressure measurement.
The Helmsley award recognizes outstanding work of early-career professionals and trainees engaged in Type 1 diabetes research and care.
Kuhadiya accepted the award at the 2014 annual meeting of the International Congress of Endocrinology and the Endocrine Society, where he showcased his research in June.
Kuhadiya also presented his findings at the American Association of Clinical Endocrinology meeting in May in Las Vegas; the online medical information and education service Medscape cited his work as one of the top news stories to come out of the meeting.
Kuhadiya completed his postgraduate work in the Division of Endocrinology, Diabetes and Metabolism.